

LRRC19 RABBIT PAB

货号: S218099

产品全名: LRRC19 兔多抗

基因符号

UNIPROT ID: Q9H756 (Gene Accession - BC126156)

背景: LRRC19 is a member of the extracellular leucine-rich repeat superfamily, a family of proteins that are thought to have diverse functions such as cell adhesion, signaling, and innate immunity. LRRC19 is closely related to the Toll-like receptors (TLRs), especially TLR3. LRRC19 does not contain a cytoplasmic Toll/IL-1 receptor (TIR) domain, but can activate NF-kappaB and induce the production of proinflammatory cytokines after stimulation with the TLR3 and other TLR ligands, suggesting that LRRC19 may play a role in the recognition and the response to certain pathogenic microorganisms. LRRC19 has also been suggested to be a potential biomarker for pancreatic tumor sensitivity to the anti-cancer, small molecule Src inhibitor AZD0530.

抗原: Fusion protein of human LRRC19

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 25-100; ELISA: 5000-10000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Signal Transduction, Epigenetics and Nuclear Signaling


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human esophagus cancer tissue using 218099(LRRC19 Antibody) at a dilution of 1/25(Cytoplasm).



In comparison with the IHC on the left, the same paraffin-embedded Human esophagus cancer tissue is first treated with the fusion protein and then with 218099(Anti-LRRC19 Antibody) at dilution 1/25.



The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using 218099(Anti-LRRC19 Antibody) at a dilution of 1/25.



In comparison with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with fusion protein and then with D223707(Anti-LRRC19 Antibody) at dilution 1/25.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
